Xie et al. reported a nanoluciferase assay in Vero E6 cells for SARS-CoV-2 that returned an EC50>10µM and CC50 >50µM for bictegravir . This assay also found that remdesivir and chloroquine were highly active, although responses in human clinical trials have been less than impressive. However, remdesivir has received emergency use authorization for the treatment of Covid-19 infections. As summarized in Figure , tipranavir also exhibits a relatively broad spectrum of antiviral activity. It was shown to inhibit replication of SARS-CoV-2 in VeroE6 cells, but the SI was relatively low (EC50 = 13 μM, CC50 = 77 μM, SI = 6) . There are no experimental studies showing pimozide inhibits the SARS-CoV-2 helicase. Vatansever et al. identified pimozide as a basic molecule that raises endosomal pH to interfere with SARS-CoV-2 entry into the human cell host, and measured an IC50 against M pro of 42 ± 2µM .